Aurobindo Pharma share price gained more than a percent in morning on Tuesday on receiving approval from South African Health regulator for latest fixed dose triple combination tablets.
“Company has received approval from the South African Health Products Regulatory Authority (SAHPRA) for its Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) tablets, 50mg/300mg/300mg, the first-line preferred regimen for HIV patients as per latest WHO guidelines,” it said in its BSE filing.
Aurobindo is now among the first few companies which has received approval for this product.
At 10:28 hours IST, the stock price was quoting at Rs 796.00, up Rs 6.10, or 0.77 percent on the BSE.
For more details click here – https://www.ways2capital.com/
stock tips free trial
This post first appeared on After Italy Verdict Gold Trades Higher On Safe-haven Demands; Silver Down, please read the originial post: here
